Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ACLY | P53396 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227870 | 1.00 | BRD4 (0.36) | BRD4LRRK2GPBAR1GLP1RGRM1 | |
| SCHEMBL2814523 | 0.86 | TTR (0.39) | GLP1RALDH1A1SMN1; SMN2HRH4 | |
| SCHEMBL21990471 | 0.83 | MEN1 (0.39) | BRD4LRRK2GPBAR1ALDH1A1ACLY | |
| SCHEMBL30227848 | 0.83 | MEN1 (0.39) | BRD4LRRK2GPBAR1ALDH1A1ACLY | |
| SCHEMBL3029986 | 0.81 | GPBAR1 (0.43) | BRD4LRRK2GPBAR1ALDH1A1HPGD | |
| SCHEMBL2812916 | 0.81 | KDM4E (0.41) | ALDH1A1HPGDSMN1; SMN2HRH4 | |
| SCHEMBL2810835 | 0.79 | CA12 (0.43) | GLP1RALDH1A1SMN1; SMN2 | |
| SCHEMBL30232936 | 0.76 | LCK (0.41) | BRD4GPBAR1ACLYSMN1; SMN2PROKR1 | |
| SCHEMBL584555 | 0.75 | GPBAR1 (0.49) | BRD4GPBAR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30413605 | 0.75 | GPBAR1 (0.49) | BRD4GPBAR1ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-3880676-B1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3880676-B1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2021220185-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | PFIZER INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2020100027-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | BRD4 2092/4885LRRK2 2528/4885GPBAR1 2128/4885 |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | BRD4 2762/4885LRRK2 2805/4885GPBAR1 2567/4885 |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | BRD4 2762/4885LRRK2 2805/4885GPBAR1 2567/4885 |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | BRD4 2092/4885LRRK2 2528/4885GPBAR1 2128/4885 |
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | BRD4 2092/4885LRRK2 2528/4885GPBAR1 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.